Nautilus net loss narrows 4% to $14.47 million in Q2 FY26; revenue turns to $190,000
NAUT•Commercial update
It launched an Iterative Mapping Early Access Program with Tau service offerings, adding initial sales hires and targeting pre-orders in early 2027.
Q2 FY26 financial results
Nautilus Biotechnology posted a net loss of USD 14.47 million for Q2 2026, narrowing 4% year over year, while revenue turned positive at USD 190,000.
Operating expenses fell 7% to USD 15.94 million, led by an 8% drop in research and development to USD 9.61 million.
Selling, general and administrative costs declined 6% to USD 6.33 million, while interest income slid 37% to USD 1.31 million.
